{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:48:19Z","timestamp":1784958499702,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaad.2016.07.048","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T08:14:22Z","timestamp":1475914462000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center"],"prefix":"10.1016","volume":"76","author":[{"given":"Haur Yueh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fook-Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Yi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharmotharampillai","family":"Thirumoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiu Ming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.07.048_bib1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.07.048_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis: incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2016.07.048_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.048_bib6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2016.07.048_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.07.048_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2016.07.048_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/ACI.0b013e3283630cc2","article-title":"Toxic epidermal necrolysis: the year in review","volume":"13","author":"Lee","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.07.048_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.048_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2016.07.048_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of cyclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.07.048_bib15","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.07.048_bib16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/bjd.13989","article-title":"Epidermal necrolysis: 60 years of errors and advances","volume":"173","author":"Heng","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized center","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaad.2015.08.008","article-title":"Treatment of toxic epidermal necrolysis in North America","volume":"73","author":"Dodiuk-Gad","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmaol Ther"},{"key":"10.1016\/j.jaad.2016.07.048_bib22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian J Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.07.048_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","volume":"27","author":"Imahara","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2016.07.048_bib26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib27","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2016.07.048_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2016.07.048_bib29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1365-2133.2007.08222.x","article-title":"Respiratory involvement in toxic epidermal necrolysis portends a poor\u00a0prognosis that may not be reflected in SCORTEN","volume":"157","author":"Hague","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0378-6323.38405","article-title":"SCORTEN: does it need\u00a0modification?","volume":"74","author":"Vaishampayuan","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2016.07.048_bib31","first-page":"e35","article-title":"Are multimorbidities underestimated in scoring systems of Stevens-Johnson syndrome and toxic epidermal necrolysis like in SCORTEN?","volume":"12","author":"Von Wild","year":"2012","journal-title":"Eplasty"},{"key":"10.1016\/j.jaad.2016.07.048_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.048_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.048_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000195632","article-title":"Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"29","author":"Hung","year":"2009","journal-title":"Am J Nephrol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216306004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216306004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:56Z","timestamp":1759271996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216306004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0190962216306004"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.048","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}